Goreshi Renato, Samrao Aman, Ehst Benjamin D
Department of Dermatology, Oregon Health and Science University, Portland, OR, USA.
J Drugs Dermatol. 2012 Dec;11(12):1422-6.
The use of topical medications for acne vulgaris is often limited by their irritant properties. Newer combination preparations are available and offer convenience, but irritant potential may still be a hindrance, perhaps more so with the combination of 2 agents. Few studies have compared these formulations directly for tolerability.
We sought to compare the tolerability of 2 combination topical acne products, clindamycin 1.2%-tretinoin 0.025% (CLIN/RA) gel and benzoyl peroxide 2.5%-adapalene 0.1% (BPO/ADA) gel.
CLIN/RA and BPO/ADA were applied daily to opposite sides of a subject's face for 21 days in a double-blinded fashion. Investigators' Global Assessments and study subject self-assessments of burning/stinging, itching, erythema, and dryness/scaling were collected. Transepidermal water loss (TEWL) was also measured as an objective measure of skin irritation. A mixed model analysis and repeated-measures analysis of variance were used to compare outcomes for both acne formulations.
CLIN/RA produced significantly less burning/stinging than BPO/ADA (P<.001) as well as significantly less pruritus than BPO/ ADA (P<.001). BPO/ADA caused significantly more TEWL than CLIN/RA (P=.005). There was no significant difference in the amount of erythema or the amount of dryness/scaling caused by either formulation.
CLIN/RA produced significantly less skin irritancy and TEWL than BPO/ADA.
外用药物治疗寻常痤疮常因其刺激性而受到限制。新型复方制剂已上市且使用方便,但仍可能存在刺激风险,两种药物联合使用时可能更明显。很少有研究直接比较这些制剂的耐受性。
我们旨在比较两种外用痤疮复方产品,即1.2%克林霉素-0.025%维甲酸(CLIN/RA)凝胶和2.5%过氧化苯甲酰-0.1%阿达帕林(BPO/ADA)凝胶的耐受性。
采用双盲法,将CLIN/RA和BPO/ADA每日分别涂抹于受试者面部的对侧,持续21天。收集研究者的整体评估以及研究对象对灼烧/刺痛、瘙痒、红斑和干燥/脱屑的自我评估。还测量经表皮水分流失(TEWL)作为皮肤刺激的客观指标。使用混合模型分析和重复测量方差分析来比较两种痤疮制剂的结果。
CLIN/RA产生的灼烧/刺痛明显少于BPO/ADA(P<0.001),瘙痒也明显少于BPO/ADA(P<0.001)。BPO/ADA导致的TEWL明显多于CLIN/RA(P=0.005)。两种制剂引起的红斑量或干燥/脱屑量没有显著差异。
与BPO/ADA相比,CLIN/RA产生的皮肤刺激性和TEWL明显更少。